Riskpilot← Back to searchSign inGet full accessHytest Oy
OYActiveY-tunnus 0956538-2Joukahaisenkatu 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 199446 employees
Revenue 2024
EUR 27,3M
+5% vs 2023
EBITDA margin
8.4%
-33% vs 2023
Equity ratio
53.4%
Financial strength
Net profit 2024
EUR 1,1M
+1421% vs 2023
| Revenue | EUR 27,3M | +5% |
| EBITDA | EUR 2,3M | -33% |
| Net profit | EUR 1,1M | +1421% |
| Total assets | EUR 20,3M | -15% |
| Equity | EUR 10,8M | +12% |
| Employees | 46 | — |
Legal name
Hytest Oy
Y-tunnus number
0956538-2
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. helmikuuta 1994
Share capital
EUR 10 200
Employees
46 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on kemiallisten ja bioteknisten sekä diagnostisten tuotteiden tutkimus- ja kehitystoiminta, valmistus ja kauppa sekä näiden tuotteiden vienti ja tuonti. Yhtiö voi lisäksi omistaa ja hallita teollisoikeuksia, kiinteistöjä, osakkeita, osuuksia ja muita arvopapereita, käydä niillä kauppaa sekä harjoittaa muuta liike- ja sijoitustoimintaa sekä Suomessa että ulkomailla.
Address
Joukahaisenkatu 6
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 26 618 | 32 532 | 35 613 | 26 018 | 27 263 |
| Staff expenses | −3 118 | −3 142 | −4 942 | −5 663 | −6 203 |
| EBITDA | 10 831 | 17 047 | 13 686 | 3 425 | 2 299 |
| Depreciation & amort. | −94 | −82 | −89 | −356 | −444 |
| EBIT | 10 738 | 16 965 | 13 597 | 3 069 | 1 855 |
| Net financials | 615 | −49 | −142 | −141 | 117 |
| Profit before tax | 4 956 | 5 477 | 4 602 | 100 | 1 142 |
| Tax | 1 599 | 3 383 | 2 708 | 25 | −2 |
| Net profit | 3 357 | 2 094 | 1 894 | 75 | 1 144 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 16 324 | 25 004 | 27 494 | 23 791 | 20 298 |
| Equity | 5 629 | 7 723 | 9 618 | 9 693 | 10 837 |
| Long-term debt | 312 | 277 | 252 | 254 | 374 |
| Short-term debt | 10 383 | 17 004 | 17 624 | 13 844 | 9 088 |
| Total debt | 10 695 | 17 281 | 17 876 | 14 098 | 9 462 |
EBITDA margin
8.4%
This company
15.8%
Market median
-47% vs market
20202024
Equity ratio
53.4%
This company
38.2%
Market median
+40% vs market
20202024
Return on equity
10.6%
This company
18.4%
Market median
+42% vs market
20202024
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20202024
Asset turnover
1.34×
This company
1.12×
Market median
+20% vs market
20202024
Debt / equity
0.87×
This company
0.62×
Market median
+40% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NM Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (5) | ||
MS Chief Executive Officer | Chief Executive Officer | 2002 – 2021 |
MD Person with significant control | Person with significant control | 2023 – 2026 |
PA Audit | Audit | 2002 – 2023 |
SC Confidential Clerk | Confidential Clerk | 2018 – 2021 |
JJ Chief Executive Officer | Chief Executive Officer | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairperson | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2023 | |
| Former (4) | ||
| Chairperson | 2018 – 2021 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2018 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Hytest Invest Oy
Hytest Oy (this company)Hytest Biotech (Shanghai) Co, KiinaHytest North America Inc.Limited liability company Hytest, VenäjäBoard members of Hytest Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Severina | Chief Executive Officer | 0 companies |
| Netta Maarit Keinänen | Chief Executive Officer | 0 companies |
| Michael David Berman | Person with significant control | 0 companies |
| Pekka Armas Thurén | Audit | 0 companies |
| Stanislav Chakhovich | Confidential Clerk | 0 companies |
| Juhana Jaakko Matias Rauramo | Chief Executive Officer | 0 companies |
| Jon Hindar | Chairperson | 0 companies |
| Xinsheng Li | Chairperson | 0 companies |
| Jianwen He | Board of Directors | 0 companies |
| Peter Lafeber | Board of Directors | 0 companies |
| Tommi Markus Unkuri | Board of Directors | 0 companies |
| Jukka Rainer Lehikoinen | Board of Directors | 0 companies |
| Wilhelmus Henricus Maria Luiten | Board of Directors | 0 companies |